Nasus Pharma. Every tracked FinTwit mention of $NSRX, newest first. 4 mentions since the first on Jun 1, 2026. See the price chart.
June 2026 · 4 mentions
Jun 1
InvestmentGuru — $NSRX
Small-cap biotech. Big potential.
Strong Phase 2 data, a differentiated needle-free product, and a clear catalyst path ahead with the IND filing and pivotal study.
The opp…↗
Jun 1
InvestmentGuru — $NSRX
Why are investors paying attention to $NSRX?
NS002 isn’t trying to create a new market.
It’s trying to improve an existing one.
If a patient experiencing anaphylaxis can…↗
Jun 1
InvestmentGuru — $NSRX is one of the more interesting micro-cap biotech stories I’m tracking.
Market cap around $60M, but targeting a $2B+ epinephrine market with a needle-free intranasal alternat…↗
Jun 1
InvestmentGuru — $NSRX
One of the Most Interesting Micro-Cap Biotech Setups Heading Into 2026
Market Cap: ~$60M
Nasus Pharma is developing NS002, a needle-free intranasal epinephrine powder des…↗